RIO DE JANEIRO (Reuters) – The Brazilian public health institute handling trials for a COVID-19 vaccine developed by China’s Sinovac Biotech said on Monday that any reports on the efficacy of the shot before a Dec. 23 announcement were “mere speculation.”
The statement from the Butantan Institute, run by the Sao Paulo state government, followed a report in the Wall Street Journal that the efficacy rate for the so-called CoronaVac was higher than 50%, citing unnamed sources.
(Reporting by Pedro Fonseca; Writing by Marcelo Rochabrun; Editing by Brad Haynes)
